MARKET

BMEA

BMEA

Biomea Fusion, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.15
-0.83
-6.93%
Closed 16:00 07/01 EDT
OPEN
11.93
PREV CLOSE
11.98
HIGH
11.93
LOW
10.67
VOLUME
134.34K
TURNOVER
898.83K
52 WEEK HIGH
16.28
52 WEEK LOW
2.840
MARKET CAP
325.23M
P/E (TTM)
-6.0743
1D
5D
1M
3M
1Y
5Y
Biomea Fusion Commences Initial-Stage Study For Plasma Cell Cancer Setting
Biomea Fusion (NASDAQ: BMEA) has dosed the the first patient in the multiple myeloma (MM) cohort of the Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor. Multiple myeloma (MM) is a cancer of plasma cells, which make antibodies (immunog...
Benzinga · 06/22 15:27
Biomea Fusion begins dosing in multiple myeloma therapy trial
Biomea Fusion (NASDAQ:BMEA) said on Wednesday the first patient had been dosed in the Phase I study evaluating BMF-219 in multiple myeloma cohort of the trial. (BMEA) stock rose 5%. The company will
Seekingalpha · 06/22 14:49
Biomea Fusion Announces First Patient Dosed In Multiple Myeloma Cohort Of COVALENT-101 Trial
BMF-219, a covalent menin inhibitor, is the first menin inhibitor administered to patients with relapsed/refractory (R/R) multiple myeloma (MM) Patients with R/R MM and R/R diffuse large B-cell lymphoma (DLBCL) are
Benzinga · 06/22 12:33
Biomea Fusion Doses First Patient in Multiple Myeloma Cohort of Phase 1 Trial of BMF-219
MT Newswires · 06/22 09:58
How Much Of Biomea Fusion, Inc. (NASDAQ:BMEA) Do Institutions Own?
The big shareholder groups in Biomea Fusion, Inc. ( NASDAQ:BMEA ) have power over the company. Generally speaking, as a...
Simply Wall St. · 06/06 17:10
BRIEF-Biomea Fusion Presents Novel Preclinical Data At ADA 2022 Suggesting BMF-219'S Potential As An Oral, Long-Acting Treatment For Type 2 Diabetes
reuters.com · 06/04 17:35
Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and function, thereby increasing insulin levels and controlling high glucose levelsBMF-219, a covalent menin inhibitor, showed stron...
GlobeNewswire · 06/04 15:00
Biomea Fusion to Participate in Jefferies Healthcare Conference
REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with ge...
GlobeNewswire · 06/02 22:00
More
No Data
Learn about the latest financial forecast of BMEA. Analyze the recent business situations of Biomea Fusion, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BMEA stock price target is 19.50 with a high estimate of 24.00 and a low estimate of 16.00.
High24.00
Average19.50
Low16.00
Current 11.15
EPS
Actual
Estimate
-0.48-0.36-0.24-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 50
Institutional Holdings: 18.41M
% Owned: 63.10%
Shares Outstanding: 29.17M
TypeInstitutionsShares
Increased
20
2.27M
New
10
211.68K
Decreased
12
121.80K
Sold Out
10
1.28M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Thomas Butler
President/Co-Founder/Chief Operating Officer/Director
Rainer Erdtmann
Chief Financial Officer/Chief Accounting Officer
Franco Valle
Independent Director
Eric Aguiar
Independent Director
Bihua Chen
Independent Director
Michael Hitchcock
Independent Director
Sumita Ray
No Data
No Data
About BMEA
Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical irreversible programs for the treatment of select cancers.

Webull offers kinds of Biomea Fusion Inc stock information, including NASDAQ:BMEA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMEA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMEA stock methods without spending real money on the virtual paper trading platform.